Cannasouth is a biopharmaceutical research and development company based in Waikato, New Zealand. The company has been established to focus on the commercial development of the medicinally beneficial attributes of cannabinoid compounds such as CBD, THC and associated chemical structures that are produced by the cannabis plant. The goal is the development of next-generation cannabinoid medicines that support patients' health outcomes and improve quality of life. Cannasouth products will be produced under GMP & ISO using environmentally friendly methods without the use of harmful chemicals or solvents, ensuring patients are treated with pure cannabinoid therapeutic compounds of the highest quality.
|Recording and Presentation of Investor Call||Thu, Nov 30 2023 10:21 am||MKTUPDTE|
|Cannasouth Investor Call||Mon, Nov 27 2023 03:13 pm||GENERAL|
|Cannasouth Announces Opening of Rights Offer||Wed, Nov 22 2023 09:13 am||OFFER|
|Launch of rights issue and revenue guidance||Mon, Nov 13 2023 01:57 pm||OFFER|
|CBD to Issue up to $5 million in Secured Convertible Notes||Thu, Nov 02 2023 04:11 pm||ADMIN|
|Cannasouth to Sell Verified Dried Cannabis Flower||Tue, Oct 31 2023 09:00 am||MKTUPDTE|
|Successful Verification for Oral Solution Products||Fri, Oct 27 2023 02:15 pm||MKTUPDTE|
|Cannasouth Announces Integration Restructure||Tue, Oct 03 2023 08:30 am||MKTUPDTE|
|Cannasouth exports first Cannabis-based API||Thu, Sep 14 2023 08:30 am||MKTUPDTE|
|Publication of Research Report||Mon, Sep 04 2023 11:47 am||MKTUPDTE|
|14/02/22||Nicholas Jon Foreman||24,162,149||21.07||17.61|
The S&P/NZX 50 Index closed at 11,496.61, up 33.12 points or 0.29%.
The carrier has bought an all-electric aircraft from Beta Tech, to be delivered in 2026.
The prestigious Deloitte Top 200 Awards winners were revealed on Wednesday evening.